SEARCH RESULTS

340304 RESULTS

PAPER Imamura K, Izumi Y, Egawa N, Ayaki T, Nagai M, Nishiyama K, Watanabe Y, Murakami T, Hanajima R, Kataoka H, Kiriyama T, Nanaura H, Sugie K, Hirayama T, Kano O, Nakamori M, Maruyama H, Haji S, Fujita K, Atsuta N, Tatebe H, Tokuda T, Takahashi N, Morinaga A, Tabuchi R, Oe M, Kobayashi M, Lobello K, Morita S, Sobue G, Takahashi R, Inoue H

Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study.

BMJ Open. 2024 Oct 26;14(10):e082142. PubMed.

PAPER Godoy-Corchuelo JM, Ali Z, Brito Armas JM, Martins-Bach AB, García-Toledo I, Fernandez-Beltrán LC, Lopez-Carbonero JI, Bascunana P, Spring S, Jimenez-Coca I, Muñozde Bustillo Alfaro RA, Sanchez-Barrena MJ, Nair RR, Nieman BJ, Lerch JP, Miller KL, Ozdinler HP, Fisher EM, Cunningham TJ, Acevedo-Arozena A, Corrochano S

Corrigendum to "TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43" [Neurobiology of disease Volume 193, April 2024, 106437].

Neurobiol Dis. 2024 Oct 26;:106708. PubMed. Corrected paper.

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE